Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more
Anatara Lifesciences Ltd (ANR) - Net Assets
Latest net assets as of June 2025: AU$535.97K AUD
Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has net assets worth AU$535.97K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.15 Million) and total liabilities (AU$612.42K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$535.97K |
| % of Total Assets | 46.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.01% |
| 10-Year Change | -96.02% |
| Growth Volatility | 58.93 |
Anatara Lifesciences Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Anatara Lifesciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anatara Lifesciences Ltd (2011–2025)
The table below shows the annual net assets of Anatara Lifesciences Ltd from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$535.97K | -60.72% |
| 2024-06-30 | AU$1.36 Million | +47.59% |
| 2023-06-30 | AU$924.54K | -32.23% |
| 2022-06-30 | AU$1.36 Million | -64.38% |
| 2021-06-30 | AU$3.83 Million | +34.08% |
| 2020-06-30 | AU$2.86 Million | -51.71% |
| 2019-06-30 | AU$5.92 Million | -31.11% |
| 2018-06-30 | AU$8.59 Million | -28.56% |
| 2017-06-30 | AU$12.02 Million | -10.79% |
| 2016-06-30 | AU$13.48 Million | +145.86% |
| 2015-06-30 | AU$5.48 Million | -24.15% |
| 2014-06-30 | AU$7.23 Million | +2674.71% |
| 2013-06-30 | AU$-280.65K | -192.35% |
| 2012-06-30 | AU$-96.00K | -500.00% |
| 2011-06-30 | AU$-16.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anatara Lifesciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2374611700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$24.15 Million | 4505.28% |
| Other Comprehensive Income | AU$416.88K | 77.78% |
| Total Equity | AU$535.97K | 100.00% |
Anatara Lifesciences Ltd Competitors by Market Cap
The table below lists competitors of Anatara Lifesciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BURGENLAND HOLDING
BE:BH4
|
$718.80K |
|
Zamp S.A.
SA:ZAMP3
|
$718.92K |
|
Findev Inc
PINK:TNSGF
|
$718.98K |
|
Chosun Welding Pohang Co. Ltd.
KQ:120030
|
$719.74K |
|
ONEOK (ONK.SG)
STU:ONK
|
$718.41K |
|
AVILA ENERGY CORP.
F:6HQ0
|
$718.38K |
|
Happy Creek Minerals Ltd
PINK:HPYCF
|
$718.27K |
|
Scryb Inc
PINK:SCYRF
|
$718.02K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anatara Lifesciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,364,573 to 535,968, a change of -828,605 (-60.7%).
- Net loss of 1,954,702 reduced equity.
- Other comprehensive income increased equity by 138,851.
- Other factors increased equity by 987,246.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-1.95 Million | -364.7% |
| Other Comprehensive Income | AU$138.85K | +25.91% |
| Other Changes | AU$987.25K | +184.2% |
| Total Change | AU$- | -60.72% |
Book Value vs Market Value Analysis
This analysis compares Anatara Lifesciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | AU$-0.03 | AU$0.01 | x |
| 2014-06-30 | AU$0.36 | AU$0.01 | x |
| 2015-06-30 | AU$0.15 | AU$0.01 | x |
| 2016-06-30 | AU$0.28 | AU$0.01 | x |
| 2017-06-30 | AU$0.24 | AU$0.01 | x |
| 2018-06-30 | AU$0.17 | AU$0.01 | x |
| 2019-06-30 | AU$0.11 | AU$0.01 | x |
| 2020-06-30 | AU$0.05 | AU$0.01 | x |
| 2021-06-30 | AU$0.06 | AU$0.01 | x |
| 2022-06-30 | AU$0.02 | AU$0.01 | x |
| 2023-06-30 | AU$0.01 | AU$0.01 | x |
| 2024-06-30 | AU$0.01 | AU$0.01 | x |
| 2025-06-30 | AU$0.00 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anatara Lifesciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -364.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -201.63%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 2.14x
- Recent ROE (-364.70%) is below the historical average (-92.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -205.99% | 1.24x | 0.00x | AU$-157.33K |
| 2014 | -11.94% | -958.73% | 0.01x | 1.03x | AU$-1.59 Million |
| 2015 | -32.75% | -887.45% | 0.04x | 1.03x | AU$-2.34 Million |
| 2016 | -5.37% | -29.57% | 0.18x | 1.03x | AU$-2.07 Million |
| 2017 | -14.18% | -59.75% | 0.23x | 1.02x | AU$-2.91 Million |
| 2018 | -41.56% | -55188.12% | 0.00x | 1.14x | AU$-4.43 Million |
| 2019 | -48.49% | -432.36% | 0.10x | 1.08x | AU$-3.46 Million |
| 2020 | -117.78% | 0.00% | 0.00x | 1.17x | AU$-3.65 Million |
| 2021 | -52.11% | 0.00% | 0.00x | 1.13x | AU$-2.38 Million |
| 2022 | -185.61% | 0.00% | 0.00x | 1.30x | AU$-2.67 Million |
| 2023 | -218.83% | 0.00% | 0.00x | 1.54x | AU$-2.12 Million |
| 2024 | -106.35% | -225.34% | 0.39x | 1.22x | AU$-1.59 Million |
| 2025 | -364.70% | -201.63% | 0.84x | 2.14x | AU$-2.01 Million |
Industry Comparison
This section compares Anatara Lifesciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $34,693,469
- Average return on equity (ROE) among peers: -62.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anatara Lifesciences Ltd (ANR) | AU$535.97K | 0.00% | 1.14x | $718.75K |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |